IOncology

The 17th Yanzhao Breast Cancer Forum was held in Shijiazhuang from August 26 to 30, 2026. Continuing the forum's longstanding academic tradition, this year's meeting featured a series of lectures by leading experts from across China, who engaged in in-depth discussions on key topics in breast cancer diagnosis and treatment, as well as specialty development. The multidisciplinary team (MDT) case discussion session was another major component of the forum, focusing on the central role of MDT in the comprehensive management of breast cancer and examining the current status and challenges of extending MDT services to primary-level hospitals. During the meeting, Oncology Frontier invited Professor Zhenchuan Song of the Fourth Hospital of Hebei Medical University to share his insights into the academic highlights of the expert lecture series and specialty development, the core value of MDT in comprehensive patient management, and the challenges and strategies involved in promoting MDT at the grassroots level.

The 2026 CSCO Annual Meeting was held in Jinan from September 16 to 19, bringing together scholars from around the world in its international sessions. Prof. Kai-Keen Shiu of the UCL Cancer Institute delivered a special lecture titled “Immuno-resistant CRC treatment” at the conference. Oncology Frontier–UroStream conducted an exclusive interview with him on site, systematically covering the core mechanisms of immunotherapy-resistant colorectal cancer (CRC), breakthrough strategies for microsatellite-stable (MSS) tumors, and practical experience in biomarker testing and patient management. He also shared his assessment of China’s progress in precision therapy and immunotherapy, as well as his expectations for future China–international collaboration, providing valuable reference for CRC treatment in China.

Hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer is the most common molecular subtype of breast cancer. For decades, the combination of endocrine therapy and chemotherapy was considered a therapeutic “forbidden zone” because of its theoretical basis and early clinical evidence. With the emergence of novel endocrine agents, chemotherapeutic drugs, antibody–drug conjugates (ADCs), and evolving treatment strategies, this traditional view is gradually being challenged. In recent years, metronomic chemotherapy has emerged as a promising approach to combining chemotherapy with endocrine therapy because of its distinctive antiangiogenic and immunomodulatory mechanisms and favorable safety profile. The MECCA and SYSUCC-020 studies have provided important evidence supporting this strategy in the first-line setting and among patients previously treated with CDK4/6 inhibitors, respectively.

The 2026 Chinese Society of Clinical Oncology (CSCO) Annual Meeting showcased cutting-edge advances in oncology worldwide, with China's innovative drug development attracting particular attention. China has become an increasingly important force in global cancer research and treatment. During the meeting, Oncology Frontier invited Professor Heinz-Josef Lenz of USC Norris Comprehensive Cancer Center and Mr. George Yuan, Executive Vice President of HUTCHMED, to engage in an in-depth dialogue under the theme “Upholding Core Principles and Driving Innovation: Moving Forward Together.”

The 29th Chinese Society of Clinical Oncology (CSCO) Annual Meeting was held in Jinan from September 16 to 19, 2026, bringing together leading oncology experts from around the world to explore pathways for innovation and advancement in precision cancer care. Professor Franco Cavalli, President of the International Conference on Malignant Lymphoma (ICML) and Professor at the Oncology Institute of Southern Switzerland in Bellinzona, was invited to attend the meeting and deliver a special presentation. As an internationally renowned expert who has devoted decades to oncology, Professor Cavalli has witnessed more than 30 years of transformation in Chinese oncology since his first visit to China in 1989. In an interview with Oncology Frontier – Hematology Frontier, he reflected on his longstanding exchanges and collaboration with the Chinese oncology community, shared key advances and future directions in extranodal lymphoma, and previewed the major topics to watch at ICML 2027.

The Pujiang Prostate Cancer Academic Conference was recently held in Shanghai. Under the theme “Standardization, Precision, Chinese Innovation, and Global Collaboration,” the conference provided a high-level platform for academic exchange, focusing on key topics including early screening and precision diagnosis of prostate cancer, optimization of local treatment strategies, innovation in advanced disease management, and the development of comprehensive care systems. By fostering deeper integration between clinical practice and cutting-edge research, the conference aimed to further advance the standard of prostate cancer care in China.

The 2026 Pujiang Urologic Oncology Academic Conference was held in Shanghai. The rapid development of antibody–drug conjugates (ADCs) and immunotherapy is moving the treatment of urothelial carcinoma beyond later-line advanced disease to first-line treatment, the perioperative setting, and even non-muscle-invasive disease. At the same time, the clinical introduction of ADCs with multiple targets and payloads has raised new challenges, including treatment sequencing, cross-resistance, and cumulative toxicity. Oncology Frontier – UroStream invited Professor Xiaojie Bian of Fudan University Shanghai Cancer Center for an interview to discuss the earlier use of ADCs, sequencing strategies, perioperative investigations, and comprehensive safety management throughout the treatment continuum.

Precise suturing is a key foundation for high-quality reconstruction in minimally invasive surgery. During laparoscopic radical prostatectomy, vesicourethral anastomosis tests the surgeon's ability to control needle-holding angles and needle trajectories, while directly affecting procedural stability and reproducibility. In this interview, Oncology Frontier – UroStream invited Professor Zhenghua Ju of Fujian Cancer Hospital to discuss the technical challenges of laparoscopic vesicourethral anastomosis, the evolution of the 360° suturing theory into the “Three Fundamental Principles of Surgical Suturing,” and the clinical value of standardized dissemination and training.

The 2026 Pujiang Prostate Cancer Academic Conference was successfully held in Shanghai under the central theme of “Standardization, Precision Breakthroughs, Chinese Innovation, and Global Collaboration.” The conference aimed to promote the standardized diagnosis and treatment of prostate cancer in China while advancing key technological innovations. Following the meeting, Oncology Frontier – UroStream invited Professor Hongkai Wang of Fudan University Shanghai Cancer Center to discuss recent innovations in robotic radical prostatectomy, balancing oncological control with functional preservation, and the development of domestically developed surgical robots.

Treatment decisions for advanced renal cell carcinoma (RCC) are shifting from traditional clinical risk stratification toward precision classification based on molecular characteristics. What is the scientific rationale behind this trend? Which key molecular biomarkers hold the greatest promise for guiding treatment selection and sequencing? And what are the major obstacles to translating scientific discoveries in precision medicine into clinical practice?